Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Tecentriq (atezolizumab) Disease area(s): Oncology Manufacturer(s): Roche 2024 Sales (USD): $4.13 billion Why it sold so well: In 2024, Roches cancer immunotherapy Tecentriq posted global sales of CHF 3.64 billion ($4.13 billion) and was the companys fourth best-selling drug after MS drug Ocrevus, hemophilia treatment Hemlibra and eye drug Vabysmo
Each COA includes third-party HPLC purity chromatograms, Mass Spectrometry structural identity validation, and quantitative LAL endotoxin testing results
Because eyes are more than just a feature - theyre the center of your expression, and they deserve expert care tailored to their unique needs
This is why its often found in hair growth serums
Genetic subtyping of obesity reveals biological insights into the uncoupling of adiposity from its cardiometabolic comorbidities
US$ 27.91
US$ 27.42
US$ 26.78
US$ 22.42
